Percheron Therapeutics (AU:PER) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Percheron Therapeutics Limited announced the results of its Annual General Meeting, where all resolutions were decided by a poll. Notably, the adoption of the Remuneration Report was met with more than 25% opposition, marking a first strike under Australian corporate law. The company continues to focus on its lead therapy for Duchenne Muscular Dystrophy, with new trial data expected soon.
For further insights into AU:PER stock, check out TipRanks’ Stock Analysis page.